文|吴理想来源|财富独角兽医药股的大牛市中,相关的主题基金也赚得盆满钵盈,一方面是多只主题基金实现翻倍,暂时排在首位的是长城医药产业精选,9月12日的最新年内收益率达到116.53%;另一方面是榜尾端的部分基金几乎年内零收益,比如前海开源中药研究精选年内下跌-2.49%,再比如2022年成立的泰康医疗健康,目前年内的净值增长率约为2.34%。01长城医药产业、华安医药生物双双受益于港股创新药到9月...
Source Link文|吴理想来源|财富独角兽医药股的大牛市中,相关的主题基金也赚得盆满钵盈,一方面是多只主题基金实现翻倍,暂时排在首位的是长城医药产业精选,9月12日的最新年内收益率达到116.53%;另一方面是榜尾端的部分基金几乎年内零收益,比如前海开源中药研究精选年内下跌-2.49%,再比如2022年成立的泰康医疗健康,目前年内的净值增长率约为2.34%。01长城医药产业、华安医药生物双双受益于港股创新药到9月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.